Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior glycemic control and weight reduction compared to semaglutide and insulin in patients with type 2 diabetes.
For patients with type 2 diabetes, especially those with cardiovascular risks or obesity, tirzepatide offers a powerful once-weekly treatment option. It significantly lowers blood sugar and promotes substantial weight loss, often outperforming other common medications like semaglutide or insulin. While cost and injection concerns exist, the clinical benefits for glycemic control and weight management are substantial.
Tirzepatide is a novel once-weekly injectable single-peptide molecule with glucose-dependent insulinotropic polypeptide and GLP-1 RA activity. The combined action at both receptors may act synergistically, providing additional effects on glycaemic control and body weight reduction.
Why this rating
Based on multiple randomized clinical trials (SURPASS-1 to -5) cited in the review.
Source
Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes
Luis Alberto Vázquez et al. · Diabetes Therapy · 2023
DOI 10.1007/s13300-023-01467-5
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →